Home Current Issue Previous Issues Published Ahead-of-Print CME Collections Podcasts For Authors Journal Info
Skip Navigation LinksHome > August 2012 - Volume 55 - Issue 2 > Commentaries on “Workshop Report: Developing a Pediatric In...
Journal of Pediatric Gastroenterology & Nutrition:
doi: 10.1097/MPG.0b013e31826050a3
Invited Commentary

Commentaries on “Workshop Report: Developing a Pediatric Inflammatory Bowel Diseases Network and Data Platform in Canada”: NETWORKS OF THE FUTURE

Moran, Christopher J.; Kaplan, Jess L.; Winter, Harland S.

Free Access
Article Outline
Collapse Box

Author Information

Mass General Hospital for Children, Boston, MA.

Address correspondence and reprint requests to Harland S. Winter, MD, Mass General Hospital for Children, Boston, MA (e-mail: hwinter@partners.org).

Received 18 February, 2012

Accepted 28 February, 2012

The authors report no conflicts of interest.

The causes of inflammatory bowel disease (IBD) remain elusive, and as a result, so does a cure. Investigations involving young children with IBD, who are exposed to fewer environmental triggers before disease onset, may yield critical information about disease pathogenesis. Unfortunately, innovative pediatric studies are often limited by small cohorts that are underpowered, especially when advanced technology is used and the focus of IBD research shifts toward systems biology approaches using microbiome, genome, and other “omics” analyses.

Although large collaborative networks and linked biorepositories hold significant value for researchers, the devil is in the details. Universal oversight must ensure consistency in data entry, and databases must be scrutinized frequently to guarantee the accuracy of clinical information such as disease reclassification and changes in disease phenotype without compromising patient confidentiality (1). Furthermore, systematic analyses of biospecimens require symmetry in sample collection, processing, and storage to avoid artifactual variation, particularly when assessing biomarkers (2–4).

We commend the work of Sherman et al (5), who identify key obstacles in creating a large-scale IBD collaborative. These endeavors represent an enormous undertaking that requires the passion of local investigators to maintain the integrity of their participating site. This proposal's objectives are comprehensive and would facilitate the study of factors associated with disease onset, progression, and effective treatment. Adequate support for data collectors and executive leadership could ultimately affect the quality of data. Well-planned and well-maintained disease-specific networks are vital to producing high-impact, transformative research that will undoubtedly lead to improved care for our patients with IBD.

Back to Top | Article Outline

REFERENCES

1. National Cancer Institute Best Practices for Biospecimen Resources. http://biospecimens.cancer.gov/practices/2011bp.asp. Accessed February 8, 2012.

2. Jackson DH, Banks RE. Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin Appl 2010; 4:250–270.

3. Ransohoff DF. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005; 5:142–149.

4. McLerran D, Grizzle WE, Feng Z, et al. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 2008; 54:44–52.

5. Sherman PM, Brown S, Rose K, et al. Workshop report: developing a pediatric inflammatory bowel diseases network and data platform in Canada. J Pediatr Gastroenterol Nutr 2012;55:125–30.

© 2012 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

Login

Article Tools

Share

Connect With Us

 

 

Twitter

twitter.com/JPGNonline

 

Visit JPGN.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.